Nebenwirkungen · Cabometyx
CABOMETYX 20 mg film-coated tablets CABOMETYX 40 mg film-coated tablets CABOMETYX 60 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 15
HOS-135846 · Präparat HOS-097776
Description of selected adverse reactions Data for the following reactions are based on patients who received CABOMETYX 60 mg orally once daily as monotherapy in the pivotal studies in RCC following prior VEGF-targeted therapy and in treatment-naïve RCC, in HCC following prior systemic therapy, in DTC in patient refractory or not eligible to radioactive iodine (RAI) who have progressed during or after prior systemic therapy, in progressive NET following prior systemic therapy or in patients who received CABOMETYX 40 mg orally once daily in combination with nivolumab in first-line advanced RCC (section 5.1).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-15T11:33:00Z · SHA-256 75b3684a4980d5ee2ff31505925f006912a1c3bf01944a70f1a39cc9a2e2e444 · Passage 2b1499aaa2c582a92a321d1fd66f825f45e25a6309247869f3307e2c3f7276c0 · Zeichen 12661–13275 im Abschnitt